The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease
Open accessPublished version of a preprint
The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Background: The effect of the COVID-19 pandemic on people with Parkinson’s disease (PD) is poorly understood. Objective: To rapidly identify areas of need and improve care in people with PD during the COVID-19 pandemic, we deployed a survey to assess COVID-19 symptoms and the pandemic’s effect among those with and without COVID-19. Methods: People with and without PD participating in the online study Fox Insight (FI) were invited to complete a survey between April 23 and May 23, 2020. Among people reporting COVID-19 diagnoses, we compared symptoms and outcomes in people with and without PD. Among people not reporting COVID-19, we assessed access to healthcare and services and PD symptoms. Results: 7,209/9,762 active FI users responded (approximately 74% response rate), 5,429 people with PD and 1,452 without PD. COVID-19 diagnoses were reported by 51 people with and 26 without PD. Complications were more frequent in people with longer PD duration. People with PD and COVID-19 experienced new or worsening motor (63%) and nonmotor (75%) symptoms. People with PD not diagnosed with COVID-19 reported disrupted medical care (64%), exercise (21%), and social activities (57%), and worsened motor (43%) and non-motor (52%) symptoms. Disruptions were more common for those living alone, with lower income and non-White race. Conclusions: The COVID-19 pandemic is associated with wide-ranging effects on people with PD, and certain groups may be at particular risk. FI provides a rapid, patient-centered means to assess these effects and identify needs that can be used to improve the health of people with PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, COVID-19 exacerbates both motor and nonmotor symptoms in PD patients, particularly urinary issues and fatigue.285,286”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [286]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The social isolation imposed by the COVID-19 pandemic greatly affected people with PD (Brown et al., 2020; van der Heide et al., 2020).”
From Online Mindfulness-Based Cognitive Therapy for People with Parkinson’s Disease and Their Caregivers: a Pilot Study (2022) · cites this paper as Brown et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Psychological Impact of Quarantine and How to Reduce It: Rapid Review of the Evidence
Brooks, S. K., Webster, R. K., Smith, L. E., Woodland, L., Wessely, S., Greenberg, N., & Rubin, G. J. (2020) · doi:10.2139/ssrn.3532534 · Cited by 16,394
The psychological impact of quarantine and how to reduce it: Rapid review of the evidence
Brooks, S. K., Webster, R. K., Smith, L. E., Woodland, L., Wessely, S., Greenberg, N., & Rubin, G. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30460-8 · Cited by 16,378 · cited 1×
“In the elderly, social isolation has been associated with more rapid cognitive decline [38], and quarantine in particular can lead to lasting psychological effects [39].”
BackgroundClinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750 · cited 1×
“Exacerbation of PD symptoms during COVID-19 may in part be due to the inflammatory reaction characteristic of the disease [25].”
BackgroundNeurologic features in severe SARS-CoV-2 infection
Helms, J., Kremer, S., Merdji, H., Clere-Jehl, R., Schenck, M., Kummerlen, C., Collange, O., Boulay, C., Fafi-Kremer, S., Ohana, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2008597 · Cited by 2,674 · cited 1×
“Although COVID-19 has been associated with changes on neuroimaging [20, 21] and SARS-CoV2 RNA has been detected in cerebrospinal fluid [22,”
MethodCDC COVID-19 Response Team, CDC COVID-19 Response Team, Chow, N., Fleming-Dutra, K., Gierke, R., Hall, A., Hughes, M., Pilishvili, T., Ritchey, M., Roguski, K., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6913e2 · Cited by 1,404
Giacomelli, A., Pezzati, L., Conti, F., Bernacchia, D., Siano, M., Oreni, L., Rusconi, S., Gervasoni, C., Ridolfo, A. L., Rizzardini, G., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa330 · Cited by 1,326
Impact of sex and gender on COVID-19 outcomes in Europe
Gebhard, C., Regitz-Zagrosek, V., Neuhauser, H. K., Morgan, R., & Klein, S. L. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00304-9 · Cited by 1,306 · cited 1×
“Men with COVID-19 have been reported to have more severe disease than women [29, 30], while women may be more susceptible [31].”
BackgroundNeuropathological features of Covid-19
Solomon, I. H., Normandin, E., Bhattacharyya, S., Mukerji, S. S., Keller, K., Ali, A. S., Adams, G., Hornick, J. L., Padera, R. F., & Sabeti, P. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2019373 · Cited by 815 · cited 1×
“23], a recent autopsy series of patients that died with COVID-19—all of whom experienced altered mental status—did not find immunohistochemical evidence of encephalitis or viral invasion into brain tissue [24].”
BackgroundSmell dysfunction: a biomarker for COVID‐19
Moein, S. T., Hashemian, S. M., Mansourafshar, B., Khorram‐Tousi, A., Tabarsi, P., & Doty, R. L. (2020) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22587 · Cited by 794 · cited 2×
“Hyposmia has been well described in people with COVID-19 [26].”
BackgroundResultAssociation of olfactory dysfunction with risk for future Parkinson's disease
Ross, G. W., Petrovitch, H., Abbott, R. D., Tanner, C. M., Popper, J., Masaki, K., Launer, L., & White, L. R. (2008) · Annals of Neurology · doi:10.1002/ana.21291 · Cited by 742 · cited 1×
“Hyposmia predicts PD-associated clinical and pathological changes [47, 48].”
BackgroundSelf-citation
Research works printed but not linked: 3
- 10.1001/jama-neurol.2020.1452 · doi:10.1001/jama-neurol.2020.1452
- 10.1001/jmaneurol.2020.2581 · doi:10.1001/jmaneurol.2020.2581
- 10.1002/air.22680 · doi:10.1002/air.22680
Cited by
SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein
Albornoz, E. A., Amarilla, A. A., Modhiran, N., Parker, S., Li, X. X., Wijesundara, D. K., Aguado, J., Zamora, A. P., McMillan, C. L. D., Liang, B., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01831-0 · Cited by 180
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
“285,286 In conclusion, SARS-CoV-2 may accelerate the ageing process while increasing the risk of neurodegenerative diseases among older adults.”
Liu, L., Ni, S., Yan, W., Lu, Q.-D., Zhao, Y., Xu, Y. Y., Mei, H., Shi, L., Yuan, K., Han, Y., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101111 · Cited by 152
“We included 27 studies (132,727,798 participants) for susceptibility [20-24,30-37,108-119,132,166], 56 studies (83,097,968 participants) for illness severity [21,24,28,31,32,34,38-41,4362,83,108,110,116,117,120-138,167,169], and 115 studies (88,878,662 participants) for mortality [21,23,28,29,31,32,34,35,3844,46-48,51…”
The Impact of COVID-19 On Comorbidities: A Review Of Recent Updates For Combating It
Malik, J. A., Ahmed, S., Shinde, M., Almermesh, M. H. S., Alghamdi, S., Hussain, A., & Anwar, S. (2022) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2022.02.006 · Cited by 112
“Non-motor symptoms were reported as new or deteriorating in all domains: mood (20 % new, 51 % worsening), cognitive (7.8% new, 41 % worsening), sleep (12 % new, 59 % worsening), and autonomic dysfunction (12 % new, 59 % worsening) (Brown et al., 2020).”
InfluentialThe Role of Diet and Dietary Patterns in Parkinson’s Disease
Knight, E., Geetha, T., Burnett, D. O., & Babu, J. R. (2022) · Nutrients · doi:10.3390/nu14214472 · Cited by 111
Parkinson’s Disease and the COVID-19 Pandemic
Fearon, C., & Fasano, A. A. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202320 · Cited by 109
“Concerns over medication supply and surgical interventions for patients who require them have been raised [43, 60].”
BackgroundInfluentialHow COVID-19 will boost remote exercise-based treatment in Parkinson’s disease: a narrative review
Langer, A., Gassner, L., Flotz, A., Hasenauer, S., Gruber, J., Wizany, L., Pokan, R., Maetzler, W., & Zach, H. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00160-3 · Cited by 81
El‐Qushayri, A. E., Ghozy, S. A., Reda, A., Kamel, A. M. A., Abbas, A. S., & Dmytriw, A. A. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2278 · Cited by 68
Putri, C., Hariyanto, T. I., Hananto, J. E., Christian, K., Situmeang, R. F. V., & Kurniawan, A. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.04.019 · Cited by 64
Suzuki, K., Numao, A., Komagamine, T., Haruyama, Y., Kawasaki, A., Funakoshi, K., Fujita, H., Suzuki, S., Okamura, M., Shiina, T., et al. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212560 · Cited by 58
“Indeed,inanonline-basedstudyincluding5,429patientswithPD,43% and52%reportedworsenedmotorandnonmotor symptoms, respectively [12].”
Yu, R., & Wu, R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.943438 · Cited by 54
“It is particularly worth noting that during the COVID-19 pandemic, PD patients may be at particular risk for developing new cognitive symptoms or worsening existing cognitive symptoms, even if the patients are not infected with COVID-19 (Brown et al., 2020).”
BackgroundHuang, P., Zhang, L., Tan, Y., & Chen, S. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00337-1 · Cited by 63
“A large online study (Fox Insight) has investigated the effect of the COVID-19 pandemic on PD patients [3].”
BackgroundInfluentialFeasibility, Safety, and Effectiveness of Telerehabilitation in Mild-to-Moderate Parkinson's Disease
Bianchini, E., Onelli, C., Morabito, C., Alborghetti, M., Rinaldi, D., Anibaldi, P., Marcolongo, A., Salvetti, M., & Pontieri, F. E. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.909197 · Cited by 54
“FAB 14 (13–15); (7–15) 14 (13–15); (6-15) 14(13-15); (10–15) F (2, 44) = 1.”
Brooks, S. K., Weston, D., & Greenberg, N. L. (2021) · Public Health · doi:10.1016/j.puhe.2021.08.014 · Cited by 55
COVID-19: systemic pathology and its implications for therapy
Shen, Q., Li, J., Zhang, Z., Guo, S., Wang, Q., An, X., & Chang, H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.65911 · Cited by 53
“PD but not diagnosed with COVID-19 reported disrupted medical care (64%), exercise (21%), and social activities (57%), and worsened motor (43%) symptoms [128].”
BackgroundThe Impact of COVID ‐19 on Access to Parkinson's Disease Medication
Cheong, J. L. Y., Goh, Z. H. K., Marras, C., Tanner, C. M., Kasten, M., Noyce, A. J., & the Movement Disorders Society Epidemiology Study Group (2020) · Movement Disorders · doi:10.1002/mds.28293 · Cited by 49
Self-citationBalcı, B., Aktar, B., Buran, S., Tas, M., & Çolakoğlu, B. D. (2021) · International Journal of Rehabilitation Research · doi:10.1097/mrr.0000000000000460 · Cited by 43
de Boer, D. R., Hoekstra, F., Huetink, K. I. M., Hoekstra, T., Krops, L. A., & Hettinga, F. J. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18126342 · Cited by 46
“−/* Radtke et al. (2020) [41] Cystic Fibrosis Change in PA VAS 44.8% reported decreased PA. − Endstrasser et al. (2020) [56] Osteoarthritis Change in daily activity Tegner activity scale (TAS) Significant decreased level of activity.”
BackgroundInfluentialCubo, E., & López, P. D. D. (2022) · Brain Sciences · doi:10.3390/brainsci12121735 · Cited by 48
Bezuidenhout, L., Joseph, C., Thurston, C., Rhoda, A. J., English, C., & Conradsson, D. M. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-07968-6 · Cited by 55
“These groups are more dependent on regular rehabilitation services to sustain function, physical activity and quality of life [1, 6, 7] and often experience limited access to rehabilitation due to problems with transportation to the clinic [8, 9], particularly those with lower incomes [9].”
BackgroundVitamin D Status and Parkinson’s Disease
Barichella, M., Garrì, F., Caronni, S., Bolliri, C., Zocchi, L., Macchione, M. C., Ferri, V., Calandrella, D., & Pezzoli, G. (2022) · Brain Sciences · doi:10.3390/brainsci12060790 · Cited by 51
“High levels of ACE2 were found in dopaminergic neurons, which may imply more severe COVID-19 infection in PD patients [84].”
BackgroundBek, J., Groves, M., Leventhal, D., & Poliakoff, E. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.678124 · Cited by 40
“The coronavirus disease COVID-19 has been associated with a deterioration in PD symptoms (3, 4), and the wider effects of the pandemic may also have exacerbated the social isolation, apathy and anxiety commonly experienced in PD (5, 6).”
BackgroundThe Intersection of Parkinson’s Disease, Viral Infections, and COVID-19
Rosen, B., Kurtishi, A., Vazquez-Jimenez, G. R., & Møller, S. G. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02408-8 · Cited by 41
SARS-CoV-2 and neurodegenerative diseases: what we know and what we don’t
Lingor, P., Demleitner, A. F., Wolff, A. W., & Feneberg, E. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02500-w · Cited by 39
COVID-19 and Parkinson’s Disease: What Do We Know So Far?
Artusi, C. A., Romagnolo, A., Ledda, C., Zibetti, M., Rizzone, M. G., Montanaro, E., Bozzali, M., & Lopiano, L. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202463 · Cited by 36
“Risk factors for COVID-19 in PD: Comparison with control groups Six studies reported comparisons between PDCOVID+ and PD patients who did not develop COVID-19 (PD-COVID-) [15, 16, 20, 22, 23, 25].”
BackgroundResultInfluentialMind the gap: Inequalities in mental health care and lack of social support in Parkinson disease
Subramanian, I., Hinkle, J. T., Chaudhuri, К. R., Mari, Z. K., Fernandez, H. H., & Pontone, G. M. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.11.015 · Cited by 39
Andrenelli, E., Negrini, F., Alessandro de, S. I. R. E., Patrini, M., Lazzarini, S. G., & Ceravolo, M. G. (2021) · European Journal of Physical and Rehabilitation Medicine · doi:10.23736/s1973-9087.20.06672-1 · Cited by 33
Inequities in neurology amplified by the COVID-19 pandemic
Nolen, L. T., & Mejia, N. I. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00452-x · Cited by 31
Parkinson’s disease and COVID-19: a systematic review and meta-analysis
Khoshnood, R. J., Zali, A., Tafrishinejad, A., Ghajarzadeh, M., Ebrahimi, N., Safari, S., & Mirmosayyeb, O. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05756-4 · Cited by 32
Genetic Exchange of Lung-Derived Exosome to Brain Causing Neuronal Changes on COVID-19 Infection
Ahmed, S. S. S. J., Paramasivam, P., Kamath, S. M., Sharma, A. K., Rome, S., & Murugesan, R. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02485-9 · Cited by 33
Yehia, A., & Abulseoud, O. A. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00728-6 · Cited by 36
“Patients with Parkinson’s disease (PD) reported the occurrence or exacerbation of both motor and non-motor symptoms such as mood changes, sleep disorders, and cognitive impairment [114, 115].”
Leta, V., Boura, I., van Wamelen, D. J., Rodríguez‐Violante, M., Antonini, A., & Chaudhuri, К. R. (2022) · International review of neurobiology · doi:10.1016/bs.irn.2022.04.004 · Cited by 28
Post-COVID-19 Parkinsonism and Parkinson’s Disease Pathogenesis: The Exosomal Cargo Hypothesis
Mysiris, D. S., Vavougios, G. D., Karamichali, E., Papoutsopoulou, S., Stavrou, V. T., Papayianni, E., Boutlas, S., Mavridis, T., Foka, P., Zarogiannis, S. G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179739 · Cited by 25
“In addition, SARS-CoV-2 infection has been demonstrated to significantly worsen motor and non-motor symptoms in people with pre-existing PD [79,80].”
BackgroundChambergo‐Michilot, D., Sevillano, S. B., Torrejón, O. O. R., Ku, G. D. L. C., & Custodio, N. (2021) · European Journal of Neurology · doi:10.1111/ene.14912 · Cited by 23
“The study of Brown, 2020 assessed adults with and without PD, and subdivided it by COVID- 19 infection.”
BackgroundInfluentialSinha, S., Mittal, S., & Roy, R. (2021) · Journal of Movement Disorders · doi:10.14802/jmd.21046 · Cited by 26
COVID ‐19 and neurodegeneration: The mitochondrial connection
Denaro, C. A., Haloush, Y. I., Hsiao, S. Y., Orgera, J. J., Osorio, T., Riggs, L. M., Sassaman, J. W., Williams, S. A., Carlo, A. R. M., da Costa, R. T., et al. (2022) · Aging Cell · doi:10.1111/acel.13727 · Cited by 23
Wang, J., Dai, L., Deng, M., Xiao, T., Zhang, Z., & Zhang, Z. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03726-9 · Cited by 24
“At the same time, some studies have also emphasized that the motor symptoms of Parkinson’s disease (PD) worsen after COVID-19, and some patients need to increase the dosage of levodopa to ensure the stability of the disease [8, 10, 11].”
COVID-19 manifestations in people with Parkinson’s disease: a USA cohort
Xu, Y., Surface, M., Chan, A. K., Halpern, J., Vanegas‐Arroyave, N., Ford, B., Feeney, M. P., Kwei, K., Katus, L. E., Kuo, S., et al. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10784-3 · Cited by 23
McDaniels, B. W., & Subramanian, I. (2022) · International review of neurobiology · doi:10.1016/bs.irn.2022.03.003 · Cited by 28
“…problem of loneliness and its negative 208 Bradley McDaniels and Indu Subramanian Balci, Aktar, Buran, Tas, and Donmez Colakoglu (2021) Turkey 45 Anxiety, cognition, depression, sleep Baschi et al. (2020) Italy 65 Anxiety, apathy, cognition, depression, fatigue Brown et al. (2020) USA (80”
BackgroundCOVID-19 and Parkinson’s disease: a systematic review and meta-analysis
Afraie, M., Moradi, G., Mohammadzadeh, P., Azami, M., Riyahifar, S., & Moradi, Y. (2022) · Acta Neurologica Belgica · doi:10.1007/s13760-022-02141-6 · Cited by 27
“The hospitalization prevalence in Parkinson’s patients during the pandemic was evaluated in three studies [5, 11, 23], in which the sample size of patients with Parkinson's disease was 71,124 people, of whom 703 were hospitalized due to COVID-19.”
BackgroundMethodLi, S., Han, L., Shi, H., Chong, K. C., Zhao, S., & Ran, J. (2022) · Age and Ageing · doi:10.1093/ageing/afac277 · Cited by 25
Dance as Lifeline: Transforming Means for Engagement and Connection in Times of Social Isolation
Kelly, M. P., & Leventhal, D. (2021) · Health Promotion Practice · doi:10.1177/1524839921996332 · Cited by 25
COVID-19, ferrosenescence and neurodegeneration, a mini-review
Sfera, A., Osorio, C. P., Maguire, G. A., Rahman, L., Jafri, A., Cummings, M. A., & Maldonado, J. C. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110230 · Cited by 25
“…not been described in association with COVID-19, exacerbation of preexisting cognitive, motor and non-motor symptoms was often observed, indicating viral neurotropism (Banerjee and Viswanath, 2020; Brown et al., 2020; Heneka et al., 2020; Mao et al., 2020; Rogers et al., 2020; Jin et al., 2020).”
COVID-19 and Physical Activity Behaviour in People with Neurological Diseases: A Systematic Review
Abasıyanık, Z., Kurt, M., & Kahraman, T. (2022) · Journal of Developmental and Physical Disabilities · doi:10.1007/s10882-022-09836-x · Cited by 26
Jaiswal, V., Alquraish, D., Sarfraz, Z., Nagpal, S., Shrestha, P. S., Mukherjee, D., Guntipalli, P., Sarfraz, A., Sánchez-Velazco, D. F., Bhatnagar, A., et al. (2021) · Journal of Primary Care & Community Health · doi:10.1177/21501327211039709 · Cited by 23
Suri, J. S., Maindarkar, M. A., Paul, S., Ahluwalia, P., Bhagawati, M., Saba, L., Faa, G., Saxena, S., Singh, I. M., Chadha, P. S., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12071543 · Cited by 27
Sellner, J., Jenkins, T. M., von Oertzen, T. J., Bassetti, C. L., Beghi, E., Bereczki, D., Bodini, B., Cavallieri, F., Liberto, G. D., Helbok, R., et al. (2021) · European Journal of Neurology · doi:10.1111/ene.14741 · Cited by 19
Akinetic Mutism and Coronavirus Disease 2019: A Narrative Review
Fusunyan, M. A., Praschan, N. C., Fricchione, G. L., & Beach, S. R. (2021) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2021.08.009 · Cited by 20
“Indeed, AM has been described in patients with COVID-19 and schizophrenia, Parkinson’s disease, and Lewy body dementia after profound delirium.(4,66) Furthermore, prior neuropsychiatric illness may confer sensitivity not only to dopamine depletion but other insults such as hypoxic-ischemic injury, toxic-metabolic dist…”
Neuroprotection of exercise: P2X4R and P2X7R regulate BDNF actions
Sun, B.-X., Peng, A., Liu, P., Wang, M., Ding, H., Hu, Y., & Kang, L. (2022) · Purinergic Signalling · doi:10.1007/s11302-022-09879-x · Cited by 25
“6% of Parkinson’s disease (PD) patients in the Netherlands were less physically active since the COVID-19 lockdown, and reduced physical activity correlated with exacerbating PD symptoms (rigidity, fatigue, tremor, pain, and concentration) [1].”
BackgroundWorsened Parkinson’s Disease Progression: Impact of the COVID-19 Pandemic
Ineichen, C., Baumann‐Vogel, H., Sitzler, M., Waldvogel, D., & Baumann, C. R. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212779 · Cited by 20
“from qualitative studies suggesting an interrelation between physical activity and disease progression [14, 17, 19] and quantitative evidence that physical activity was significantly decreased during the stay-at-home mandate in PD-patients [5].”
BackgroundImpact of COVID ‐19 on long‐term outcomes in Parkinson's disease
Hadidchi, R., Al‐Ani, Y., Piskun, H., Pakan, R., Duong, K. S., Jamil, H., Wang, S. H., Henry, S. S., Maurer, C. W., & Duong, T. Q. (2025) · European Journal of Neurology · doi:10.1111/ene.70013 · Cited by 21
Outcome of Hospitalized Parkinson's Disease Patients with and without COVID ‐19
Parihar, R., Ferastraoaru, V., Galanopoulou, A. S., Geyer, H. L., & Kaufman, D. M. (2021) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13231 · Cited by 18
“Due to the smaller cohort, no significant conclusions could be drawn about the effect of non-neurologic comorbidities in patients without COVID-19.”
ResultInfluentialD’souza, J., Biswas, A., Gada, P., Mangroliya, J., & Natarajan, M. (2021) · Disability and Rehabilitation · doi:10.1080/09638288.2021.1986747 · Cited by 21
SARS-CoV-2 and Parkinson’s Disease: A Review of Where We Are Now
Boura, I., Qamar, M. A., Daddoveri, F., Leta, V., Popławska-Domaszewicz, K., Falup‐Pecurariu, C., & Chaudhuri, К. R. (2023) · Biomedicines · doi:10.3390/biomedicines11092524 · Cited by 21
“Similarly, new-onset or the deterioration of fatigue or sleep problems were reported almost three times and twice as often, respectively, among PD patients with COVID-19 compared to those without COVID-19 in the Fox Insight study [41].”
InfluentialJacquet, A. D. R., Bogard, S., Normandeau, C. P., Degroot, C., Postuma, R. B., Dupré, N., Miyasaki, J. M., Monchi, O., Martino, D., Fon, E. A., et al. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.08.018 · Cited by 20
“Living alone had previously been identified as a factor aggravating the effects of the COVID-19 pandemic in patients with PD [27], supporting our observation that lifestyle and social interactions could explain the gender effect observed.”
Gruppo di Studio “Bioetica e Cure Palliative” of the Italian Neurological Society, Zullo, S., Ingravallo, F., Crespi, V., Cascioli, M., D’Alessandro, R., Gasperini, M., Lalli, C., Lugaresi, A., Marogna, M., et al. (2021) · Neurological Sciences · doi:10.1007/s10072-020-04984-4 · Cited by 19
“As an example, the COVID-19 pandemic was associated with deleterious wideranging effects on people with Parkinson’s disease, above all those living alone, with low income or belonging to ethnic minorities [7], and this was worsened by the greater difficulty in accessing drug treatments [8], leading to inadequate sympt…”
BackgroundSeritan, A. L., Iosif, A.-M., Prakash, P., Wang, S. S., & Eisendrath, S. (2022) · Journal of Technology in Behavioral Science · doi:10.1007/s41347-022-00261-7 · Cited by 16
“The social isolation imposed by the COVID-19 pandemic greatly affected people with PD (Brown et al., 2020; van der Heide et al., 2020).”
BackgroundCavallieri, F., Sireci, F., Fioravanti, V., Toschi, G., Rispoli, V., Antonelli, F., Costantini, M., Ghirotto, L., & Valzania, F. (2021) · European Journal of Neurology · doi:10.1111/ene.14745 · Cited by 16
Changes in mortality trends amongst common diseases during the COVID-19 pandemic in Sweden
Axenhus, M., Schedin‐Weiss, S., Winblad, B. G., & Wimo, A. B. (2021) · Scandinavian Journal of Public Health · doi:10.1177/14034948211064656 · Cited by 16
“The pandemic has also caused disruptions to the daily lives of PD patients, with many reporting increases in symptoms and decreased medical access, prompting potential complications [31].”
BackgroundChaudhuri, К. R., Rukavina, K., McConvey, V., Antonini, A., Lorenzl, S., Bhidayasiri, R., Piemonte, M. E. P., Lim, S., Richfield, E. W., Walker, R. W., et al. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1923480 · Cited by 15
Krzysztoń, K., Mielańczuk-Lubecka, B., Stolarski, J., Poznańska, A., Kępczyńska, K., Zdrowowicz, A., Domitrz, I., & Kochanowski, J. (2021) · Brain Sciences · doi:10.3390/brainsci12010026 · Cited by 19
“The survey was prepared in Polish after reviewing the results and research questions of recent survey studies concerning the impact of the pandemic on people with PD conducted in other countries [17,18].”
BackgroundThe pathogenesis of Parkinson’s disease and crosstalk with other diseases
Liu, T., GUO, D., & Wei, J. (2024) · Biocell · doi:10.32604/biocell.2024.051518 · Cited by 19
COVID-19 and neurological disorders: what might connect Parkinson’s disease to SARS-CoV-2 infection
Iacono, S., Schirò, G., Davì, C., Mastrilli, S., Abbott, M., Guajana, F., Arnao, V., Aridon, P., Ragonese, P., Gagliardo, C., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1172416 · Cited by 16
“A study including 5,429 PD patients revealed the worsening of non-motor symptoms such as sleeps-disturbances, cognitive function, autonomic function, mood disorders, appetite disorders and pain (92).”
BackgroundNeurological, psychological, psychosocial complications of long-COVID and their management
Narayanan, S. N., Padiyath, S., Chandrababu, K., Raj, L., Baby Chakrapani, P. S., Ninan, G. A., Sivadasan, A., Jacobs, A. R., Li, Y. W., & Bhaskar, A. (2024) · Neurological Sciences · doi:10.1007/s10072-024-07854-5 · Cited by 21
“In another series by Brown et al. [138], among patients with Parkinsonism and COVID-19, 63% complained of motor symptoms, and 75% of non - motor symptoms, whilst among patients with Parkinsonism without COVID-19, 43% noted worsening in motor symp - toms and 52% worsening in non-motor symptoms,…”
Anghelescu, A. (2022) · Parkinson s Disease · doi:10.1155/2022/4370712 · Cited by 17
Sakibuzzaman, M., Hassan, A., Hayee, S., Haque, F. A., Bushra, S. S., Maliha, M., Tania, M. K., Sadat, A., Akter, F., Mazumder, T., et al. (2022) · Cureus · doi:10.7759/cureus.29297 · Cited by 14
Mameli, F., Zirone, E., Capetti, B., Mellace, D., Ferrucci, R., Franco, G., Fonzo, A. D., Barbieri, S., & Ruggiero, F. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.939520 · Cited by 12
“Healthcare services provided to patients with PD were swiftly adapted to the restrictive measures in place (Brown et al., 2020).”
BackgroundMeta-Analysis of the Mechanisms Underlying COVID-19 Modulation of Parkinson’s Disease
Zhang, J., Bishir, M., Barbhuiya, S., & Chang, S. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713554 · Cited by 12
“In a case–control study of 16,971 patients, PD patients with SARS-CoV-2 infection had worsening motor (63%) and non-motor (75%) symptoms compared to PD patients without SARS-CoV-2 (43% worsening motor symptoms and 52% non-motor symptoms) [18].”
ResultLong-Term Outcomes of Patients with Pre-Existing Essential Tremor After SARS-CoV-2 Infection
Pakan, R., Hadidchi, R., Al‐Ani, Y., Piskun, H., Duong, K. S., Henry, S. S., Wang, S. H., Maurer, C. W., & Duong, T. Q. (2024) · Diagnostics · doi:10.3390/diagnostics14242774 · Cited by 16
Complicaciones extrapulmonares de la enfermedad por COVID-19
Pecho‐Silva, S., Arteaga‐Livias, K., Bazán-Concha, B. E., & Navarro‐Solsol, A. C. (2020) · Revista Peruana de Investigación en Salud · doi:10.35839/repis.4.4.775 · Cited by 30
Barriers to Vaccination Among People with Parkinson’s Disease and Implications for COVID-19
Phanhdone, T., Drummond, P. S., Meisel, T., Friede, N., Rocco, A. D., Chodosh, J., & Fleisher, J. E. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202497 · Cited by 11
“Similar to influenza and pneumonia, individuals with PD—particularly the most advanced and homebound —are at an increased risk of complications from COVID-19 [10-12].”
Lau, Y. H., Lau, K. M., & Ibrahim, N. M. (2021) · Journal of Movement Disorders · doi:10.14802/jmd.21034 · Cited by 10
Parkinson’s Disease in Light of the COVID-19 Pandemic
Drelich‐Zbroja, A., Cheda, M., Kuczyńska, M., Dąbrowska, I., Kopyto, E., & Halczuk, I. (2022) · Brain Sciences · doi:10.3390/brainsci12020143 · Cited by 10
“The COVID-19 pandemic also caused a decrease in physical activity and made access to medical care more difficult, which may have contributed to an increase in motor and non-motor parkinsonism symptoms [48,49].”
BackgroundFründt, O., Hanff, A.-M., Mai, T., Kirchner, C., Mazery, E. B. D., Amouzandeh, A., Buhmann, C., Krüger, R., & Südmeyer, M. (2021) · Brain Sciences · doi:10.3390/brainsci12010062 · Cited by 10
“Global and regional studies from America (US, Canada, Brazil), Asia (China, Japan, South Korea, India, Iran Israel, Turkey), North Africa (Egypt), or European countries (Luxembourg, Netherlands, UK, Italy, Spain, Slovenia) reported wide-ranging consequences of the pandemic on PwP, such as worsened motor and non-motor…”
BackgroundLong COVID: From olfactory dysfunctions to viral Parkinsonism
Pandey, S., Bapat, V., Abraham, J. N., & Abraham, N. M. (2024) · World Journal of Otorhinolaryngology - Head and Neck Surgery · doi:10.1002/wjo2.175 · Cited by 11
“121 A retrospective longitudinal study was conducted in Egypt where the progression of the motor symptoms was measured using the MDS ‐ UPDRS ‐ Ⅲ scale (Movement Disorder Society ‐ Unified Parkinson Disease Rating Scale ‐ Ⅲ ) during the onset of COVID ‐ 19 from December 2019 to April 2020.”
Wolff, A. W., Haller, B., Demleitner, A. F., Westenberg, E., & Lingor, P. (2022) · Brain Sciences · doi:10.3390/brainsci12030353 · Cited by 10
“Restrictions on activities of daily life during the pandemic, such as home confinement or travel restrictions, have posed risks to regular medical care for PD patients [8].”
BackgroundResultVignatelli, L., Baccari, F., Belotti, L. M. B., Zenesini, C., Baldin, E., Buonaura, G. C., Cortelli, P., Descovich, C., Giannini, G., Guarino, M., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.873925 · Cited by 10
“Some empirical data consistently show a reduction in the daily walking activity during the confinement period compared to the pre-confinement period (33), the reduction in the amount, duration, and frequency of exercise (34, 35) and physiotherapy (20) in people with PD, with possible subjective and objective worsening…”
BackgroundElechi, K. W., Nkem, O. O., Chibueze, N. T., Elechi, U. S., & Kenechukwu, F. C. (2025) · Neuroscience Insights · doi:10.1177/26331055251342755 · Cited by 14
“61”
Mai, A. S., Yong, J. H., Tan, B. J., Xiao, B., & Tan, E. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51616 · Cited by 11
“35).(4,17,18,21,22,26,27,29,31,33,35,37) Worsening or newonset depression was assessed in 15 studies of 9233 patients, and we found the prevalence to be 26.”
BackgroundInfluentialMoya‐Galé, G., Pagano, G., & Walsh, S. J. (2024) · International Journal of Speech-Language Pathology · doi:10.1080/17549507.2024.2330538 · Cited by 10
“Furthermore, with the sudden onset of the global COVID-19 pandemic, the interruption of social activities, as well as access to medical care and exercise, was found to be associated with the worsening of PD-related symptoms (Brown et al., 2020).”
Movement disorders in COVID-19 times: impact on care in movement disorders and Parkinson disease
Poonja, S., Chaudhuri, К. R., & Miyasaki, J. M. (2022) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001075 · Cited by 9
Hadidchi, R., Al‐Ani, Y., Piskun, H., Pakan, R., Duong, K. S., Jamil, H., Wang, S. H., Henry, S. S., Maurer, C. W., & Duong, T. Q. (2024) · Research Square · doi:10.21203/rs.3.rs-4373059/v1 · Cited by 9
Brazilian dance self-perceived impacts on quality of life of people with Parkinson’s
Delabary, M. D. S., Sbeghen, I. L., da Silva, E. C. T., Guzzo, C. C. E., & Haas, A. N. (2024) · Frontiers in Psychology · doi:10.3389/fpsyg.2024.1356553 · Cited by 8
COVID-19 related neurological manifestations in Parkinson’s disease: has ferroptosis been a suspect?
Jia, F., & Han, J. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01915-6 · Cited by 10
“In dopaminergic neurons, which are diminished in PD patients, ACE2 is signi fi cantly expressed and may contribute to the aggravation of pre-existing symptoms or a more severe COVID-19 infection [38].”
BackgroundAlbornoz, E. A., Amarilla, A. A., Modhiran, N., Parker, S. E., Li, X. X., Wijesundara, D. K., Zamora, A. C. P., McMillan, C. L. D., Liang, B., Peng, N. Y. G., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.11.475947 · Cited by 8
Gamble, L. D., Clare, L., Martyr, A., Caulfield, M., Charlwood, C., Hulme, C. T., Oyebode, J. R., & Prina, M. A. (2025) · BMC Medicine · doi:10.1186/s12916-025-04443-x · Cited by 7
“For Parkinson’s disease, one global study found that just 12% lived alone [8], whereas some small studies in the UK indicate that 18–27% lived alone [9–12].”
Covid-19 and Parkinson's disease: Nursing care, vaccination and impact on advanced therapies
Roszmann, A., Podlewska, A. M., Lau, Y. H., Boura, I., & Hand, A. (2022) · International review of neurobiology · doi:10.1016/bs.irn.2022.04.005 · Cited by 6
COVID-19 and Comorbidities: What Has Been Unveiled by Metabolomics?
Camelo, A. L. M., Zamora-Obando, H. R., Rocha, I., Dias, A. C., Mesquita, A. D. S., & Simionato, A. V. C. (2024) · Metabolites · doi:10.3390/metabo14040195 · Cited by 10
Martini, S., Magistrelli, L., Vignaroli, F., Colombatto, F., Comi, C., & Cosentino, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113007 · Cited by 9
“Moreover, PD patients reported a lack of clinical assistance [2] and difficulties in obtaining PD medications [1,3,14].”
Backgroundda Silva, C. F., de Oliveira, J. S., da Silva, T. S., Filho, N. J. D. S., MARQUES, V. G., Tavares, R. B., ANDRADE, M. E. F. V. B., & Lins, C. C. D. S. A. (2022) · Revista de Odontologia da UNESP · doi:10.1590/1807-2577.00322 · Cited by 6
Manfredini, A., Pisano, F., Incoccia, C., & Marangolo, P. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20064889 · Cited by 6
Fereshtehnejad, S., Rodríguez‐Violante, M., Ponce-Rivera, M. S., Martínez-Ramírez, D., & Ramirez‐Zamora, A. (2022) · Behavioral Sciences · doi:10.3390/bs12110447 · Cited by 6
“The latter is associated with older age and longer disease duration [10,20].”
BackgroundImpact of COVID-19 Pandemic on Parkinson's Disease: A Tale of Fears and Sorrows!
Kumar, N., & Gupta, R. (2021) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_97_21 · Cited by 5
“Scientific literature that examined the effect of the pandemic in absence of SARS‐CoV‐2 infection among patients with existing PD supports the findings of this study.[5,14,18] COVID‐19 pandemic has also been found to worsen existing symptoms or lead to new‐onset symptoms, perhaps resulting from significant lifestyle c…”
BackgroundResultInfluentialMoving Forward from the COVID-19 Pandemic: Needed Changes in Movement Disorders Care and Research
Valdovinos, B. Y., Modica, J. S., & Schneider, R. B. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01178-7 · Cited by 6
Seshadri, S., Norton, S. A., Stahl, T. J., Shah, M., Dini, M., Yarab, N., Holtrop, J. S., & Kluger, B. M. (2022) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/10499091221119462 · Cited by 6
“Other studies have highlighted how the loss of support services during the pandemic led to worsening motor symptoms for patients and increased care partner burden.(7,9,13,19) However our study demonstrates that at the core of increased care partner “burden” was the need to choose between poor options with little guida…”
BackgroundClinical and Functional Evolution in Subjects with Parkinson’s Disease during SARS-CoV-2 Pandemic
Capecci, M., Baldini, N., Campignoli, F., Lombardo, L. P., Andrenelli, E., & Ceravolo, M. G. (2023) · Applied Sciences · doi:10.3390/app13021126 · Cited by 5
Sandeep, Subba, R., & Mondal, A. C. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03756-3 · Cited by 6
“COVID-19 exacerbates motor (balance, bradykinesia, slowed movement, stiffness, problems eating and swallowing, gait disturbances, and tremor) and non-motor (anxiety, apathy, depression, insomnia, hypersomnia, fatigue, confusion, memory deficits, and hallucinations) symptoms [24].”
Extracellular Vesicles: The Invisible Heroes and Villains of COVID‐19 Central Neuropathology
Chang, H., Chen, E., Hu, Y., Wu, L., Deng, L., Ye, S., Mao, X., Zhu, T., Liu, J., & Chen, C. (2023) · Advanced Science · doi:10.1002/advs.202305554 · Cited by 4
Perception of COVID-19 Pandemic by Brazilian People With Parkinson’s Disease and Multiple Sclerosis
Simieli, L., Santinelli, F. B., Costa, E. D. C., Kuroda, M. H., Oliveira, L. R., Penedo, T., Pilon, J., Silveira-Ciola, A. P., de Assis, I. S. A., Guelfi, É. T. N., et al. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.718313 · Cited by 7
Kataoka, H., Obayashi, K., Tai, Y., Sugie, K., & Saeki, K. (2023) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2023.100194 · Cited by 4
“This aspect was reported by a cross-sectional study using data obtained via telephone interviews about the psychological symptoms before and after COVID-19 waves [17].”
Method
Metadata
- Authors
- Brown, E. G., Chahine, L. M., Goldman, S. M., Korell, M., Mann, E., Kinel, D. R., Arnedo, V., Marek, K. L., & Tanner, C. M.
- Affiliations
- University of California, San Francisco (US)
- University of Pittsburgh (US)
- University of Rochester (US)
- Michael J. Fox Foundation (US)
- Institute for Neurodegenerative Disorders (US)
- Corresponding author
- Tanner, Caroline M.
- ORCID
- Venue
- Journal of Parkinson's Disease
- Publisher
- SAGE Publications
- Published
- 2020-10-27
- Volume
- 10
- Issue
- 4
- Pages
- 1365-1377
- ISSN
- 1877-7171 (ISSN-L)
- 1877-718X
- PMC
- PMC7683050
- OpenAlex
- W3086892979
- Cited by
- 177
- References
- 54
- Citations by year
- 2026: 4 · 2025: 18 · 2024: 29 · 2023: 25 · 2022: 49 · 2021: 48 · 2020: 4
- FWCI
- 13.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Parkinson s Disease (publishedVersion, cc-by)
- medRxiv (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- U.S. Department of Defense
- Michael J. Fox Foundation for Parkinson's Research
- Biogen
- University of Pittsburgh
- Oscar Health
- National Institutes of Health
- Centers for Disease Control and Prevention
- University of California, San Francisco
- National Institute for Occupational Safety and Health
- Agency for Toxic Substances and Disease Registry
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Oncology › COVID-19 and healthcare impacts
- Social Sciences › Psychology › Clinical Psychology › COVID-19 and Mental Health
- Keywords
- Parkinson's disease, COVID-19 pandemic, COVID-19 symptoms, motor symptoms, non-motor symptoms, health care access, living alone, income inequality, racial disparities, disease duration
- MeSH terms
- COVID-19, Adult, Aged, Aged, 80 and over, Cross-Sectional Studies, Female, Health Services Accessibility, Humans, Male, Middle Aged, Parkinson Disease, Pneumonia, Viral, Surveys and Questionnaires, Coronavirus Infections, Young Adult, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.